Immunome, Inc. (NASDAQ:IMNM – Get Rating) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 162,700 shares, a growth of 25.6% from the March 15th total of 129,500 shares. Based on an average daily trading volume, of 50,600 shares, the […]
Immunome, Inc. (NASDAQ:IMNM – Get Rating) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 129,500 shares, a decline of 11.2% from the February 28th total of 145,800 shares. Based on an average trading volume of 87,800 shares, the days-to-cover ratio is currently […]
WASHINGTON (dpa-AFX) - AbbVie (ABBV) and Immunome Inc. (IMNM) have collaborated to discover up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery
14.11.2022 - Immunome, Inc. (Nasdaq: IMNM), a clinical stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the third quarter ended .
07.11.2022 - Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it is presenting a poster at the Society for . Seite 1